INTRAVITREAL INJECTION
THERAPY

Many significant eye disorders involving the retina are treated with intravitreal injection treatment. Wet age-related macular degeneration and its variant polypoidal choroidal vasculoapthy, diabetic maculopathy, macular edema from retinal vein blockage, bleeding consequences of high short-sightedness, and other conditions fall under this category.

An intravitreal injection is an out-patient treatment in which medication is injected directly into the vitreous gel of the eye with a very small needle. This permits the drug to be given near to the macula where the disease is located, reducing leakage and limiting damage.

To keep the condition under control, multiple injections may be required. Depending on the condition being treated, intravitreal injection therapy may require the addition of laser therapy.

Eylea (Aflibercept), Lucentis (Ranibizumab), Avastin (Bevacizumab), and Ozurdex (Dexamethasone) are among the drugs available for intravitreal injection. These have been found to be beneficial in slowing and minimising the rate of vision loss. Consult with your eye specialist to determine which drug is best for you.